Document Detail

Therapeutic Advances in MicroRNA Targeting.
MedLine Citation:
PMID:  20729755     Owner:  NLM     Status:  In-Data-Review    
In the last 10 years it has become increasingly clear that a large class of small noncoding RNAs, known as microRNAs (miRNAs) are potent and crucial regulators of important cellular processes such as differentiation, growth, and survival. miRNAs regulate gene expression through binding to 3' UTRs of target messenger RNAs whereby inducing either messenger RNA degradation or inhibition of protein translation. Although we have only just begun to gain some insight into the biology surrounding miRNAs, their apparent relevance and potency during the onset and progression of disease has generated a lot of interest in assessing the feasibility of therapeutic regulation of miRNAs. As a result of the short RNA nature of miRNAs and lessons learned from small interfering RNA therapeutics and gene therapy, within a timespan of a few years, incredible progress has been made in advancing miRNA regulation into the clinic. We summarize the various therapeutic tools that are currently being investigated to manipulate miRNAs with a special focus on cardiovascular disease and speculate on the future developments of miRNA therapeutics.
Rusty L Montgomery; Eva van Rooij
Related Documents :
18162065 - Effect of alcohol on mir-212 expression in intestinal epithelial cells and its potentia...
19626115 - Modulation of microrna processing by p53.
21081925 - Mrna turnover rate limits sirna and microrna efficacy.
18945805 - Experimental identification of microrna-140 targets by silencing and overexpressing mir...
23620165 - Stable conditional expression and effect of c/ebpβ-lip in adipocytes using the pslik sy...
20596845 - Epstein-barr virus latent membrane protein 1 is not associated with vessel density nor ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  57     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1-7     Citation Subset:  IM    
From miRagen Therapeutics, Boulder, CO.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of MicroRNAs in cardiovascular disease: therapeutic challenges and potentials.
Next Document:  Effect of calcitonin gene-related peptide receptor antagonism on the systemic blood pressure respons...